!Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (numberneeded-to-treat: 6.4 over 1.8-4.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by ≥ 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in highrisk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication.

No abstract

Acute exacerbation of chronic obstructive pulmonary disease (COPD) is associated with dyspnea and, consequently, reduced mobility. Immobility is a recognized risk factor of deep-vein thrombosis (DVT), but few data exist regarding the prevalence of DVT in patients with acute exacerbation of COPD. Real-time B-mode ultrasonography (US) is a noninvasive screening method for the diagnosis of DVT. We therefore used US to investigate the prevalence of DVT in patients with an acute exacerbation of COPD. In a prospective cohort study, 196 patients with COPD were studied [110 males, 86 females, age: 66.9 ± 9.1 years, weight: 63.5 ± 12.7 kg, forced expiratory volume in 1 s (FEV₁): 0.7 ± 0.2 liters, and a ratio of FEV₁ to vital capacity (VC): 37 ± 6%] in a respiratory intensive care unit on the day of admission. Patients with reduced mobility due to other diseases were excluded. All US were performed by one experienced person with a 5-MHz linear scanner. The veins of the lower extremity were subdivided into three segments: (1) the common femoral, (2) superficial femoral veins including the long saphenous vein and (3) the popliteal vein. In 21 of 196 COPD patients (10.7%), DVT were demonstrated; 18 of these were asymptomatic. Bilateral DVT were not found. In 6 patients, additional diagnoses were: Baker’s cyst (n = 3), inguinal lymph node (n = 1) and knee joint effusion (n = 2). There were no differences between patients with and without DVT with respect to age, hemoglobin, PO₂, PCO₂, pH, FEV₁, VC or dyspnea scale. DVT in the lower extremity, which was not detectable on clinical examination, was relatively common in patients with an acute exacerbation of COPD. All clinical variables measured (age, weight, dyspnea scale, lung function, hemoglobin, hematocrit and blood gases) failed to predict patients more likely to have DVT.

No abstract

Background: Respiratory muscle weakness is one of the most important causes of hypercapnia in patients with COPD. There is evidence that stable hypercapnic patients will benefit from long-term oxygen therapy (LTOT). Objectives: The prognostic role of reversible hypercapnia in COPD is still unclear. Early implementation of LTOT in these patients may influence endurance time and mortality. Methods: In this pilot study, we investigated 28 patients (26 males, 49–74 years) with COPD, advanced airflow limitation [forced expiratory volume in 1 s (percentage of predicted value) 40.8 ± 10.2] and mild hypoxaemia (pO₂ 66.5 ± 6.3 mm Hg). All patients had developed a moderate reversible hypercapnia during an acute exacerbation or during exercise testing (peak pCO₂ 48.0 ± 2.5 mm Hg). Patients were allocated randomly to a control group (n = 14) or an LTOT group (n = 14). The two groups were well matched in terms of physiological data. Lung function, endurance time (cycle ergometer), dyspnoea score, blood gases and LTOT compliance were measured at baseline and every 6 months over a period of 3 years. Results: Endurance time increased from 6.4 ± 2.7 min at baseline to 7.1 ± 2.7 min after 1 year in the LTOT group and decreased from 6.1 ± 3.0 to 4.9 ± 3.8 min in the controls (p < 0.05). After 1 year, the end-exercise dyspnoea score was significantly lower in the LTOT group (4.5 ± 1.5) than in the controls (5.7 ± 1.9). Conclusion: COPD patients with reversible hypercapnia and mild hypoxaemia benefit from LTOT in terms of endurance time and a reduction of exertional dyspnoea after 1 year.